Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

265 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Elevation of Early Plasma Biomarkers in Patients with Clinical Risk Factors Predicts Increased Nonrelapse Mortality after Allogeneic Hematopoietic Stem Cell Transplantation.
Hotta M, Satake A, Yoshimura H, Fujita S, Katayama Y, Ota S, Hanamoto H, Oyake T, Ito S, Okada M, Nakanishi T, Ito T, Ishii K, Nomura S. Hotta M, et al. Among authors: satake a. Transplant Cell Ther. 2021 Aug;27(8):660.e1-660.e8. doi: 10.1016/j.jtct.2021.04.025. Epub 2021 May 12. Transplant Cell Ther. 2021. PMID: 33989832 Free article.
NPM1-mutation-based measurable residual disease assessment after completion of two courses of post-remission therapy is a valuable clinical predictor of the prognosis of acute myeloid leukemia.
Marumo A, Wakita S, Morita K, Oh I, Kako S, Toya T, Najima Y, Doki N, Kanda J, Kuroda J, Mori S, Satake A, Usuki K, Uoshima N, Kobayashi Y, Kawata E, Nagao Y, Shono K, Shibusawa M, Tadokoro J, Hagihara M, Uchiyama H, Kubota Y, Kimura S, Motomura S, Hashimoto A, Muto H, Sato E, Ogata M, Mitsuhashi K, Ando J, Date K, Fujiwara Y, Terada K, Yui S, Arai K, Kitano T, Miyata M, Ohashi K, Kanda Y, Yamaguchi H. Marumo A, et al. Among authors: satake a. Int J Hematol. 2022 Aug;116(2):199-214. doi: 10.1007/s12185-022-03328-6. Epub 2022 Apr 4. Int J Hematol. 2022. PMID: 35377134
Long-term outcome after allogeneic bone marrow transplantation for hematological malignancies with non-remission status. Results of a single-center study of 24 patients.
Tabata M, Satake A, Okura N, Yamazaki Y, Toda A, Nishioka K, Tanaka H, Chin M, Itsukuma T, Yamaguchi M, Misawa M, Kai S, Hara H. Tabata M, et al. Among authors: satake a. Ann Hematol. 2002 Oct;81(10):582-7. doi: 10.1007/s00277-002-0506-z. Epub 2002 Sep 26. Ann Hematol. 2002. PMID: 12424540
Blastic Epstein-Barr virus associated post-transplant lymphoproliferative disorder after allogeneic stem cell transplantation for severe aplastic anemia.
Hotta M, Nakaya A, Fujita S, Satake A, Nakanishi T, Azuma Y, Tsubokura Y, Konishi A, Yoshimura H, Ito T, Ishii K, Nomura S. Hotta M, et al. Among authors: satake a. Hematol Rep. 2018 May 16;10(2):7527. doi: 10.4081/hr.2018.7527. eCollection 2018 May 14. Hematol Rep. 2018. PMID: 30046412 Free PMC article.
Comparison of starting doses of anagrelide as a first-line therapy in patients with cytoreductive therapy-naïve essential thrombocythemia: difference between starting at 0.5 and 1.0 mg/day.
Hashimoto Y, Ito T, Tanaka Y, Nakaya A, Fujita S, Satake A, Nakanishi T, Konishi A, Hotta M, Yoshimura H, Ishii K, Hashimoto A, Kondo T, Omura H, Shinzato I, Tanaka T, Nomura S. Hashimoto Y, et al. Among authors: satake a. Int J Hematol. 2020 Jul;112(1):33-40. doi: 10.1007/s12185-020-02876-z. Epub 2020 Apr 23. Int J Hematol. 2020. PMID: 32328973
265 results